Satellos Bioscience Inc (MSCLF)

$0.66 -0.01 (-1.73%)
Market Cap 123.66M
Revenue (ttm) 0.00
Net Income (ttm) -20.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 153,300
Avg Vol 129,068
Day's Range N/A - N/A
Shares Out 185.51M
Stochastic %K 67%
Beta 1.10
Analysts Strong Buy
Price Target $0.86

Company Profile

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an...

Industry: Biotechnology
Sector: Healthcare
Address:
Royal Bank Plaza, Suite 2800 South Tower 200 Bay Street, Toronto, Canada
Florestan
Florestan Jan. 21 at 3:55 AM
$MSCLF imminent data drop on durability from the adult cohort...First returning patient dosed Oct 21, exactly 3 months ago.
0 · Reply
WBinthehouse
WBinthehouse Jan. 20 at 2:49 PM
$MSCLF up 3 cents on 4K shares. lol. Someone is walking this up to lure suckers.
1 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Jan. 18 at 12:28 AM
$MSCLF just the beginning of a massive re-rate of this stock.
0 · Reply
stevetripp
stevetripp Jan. 16 at 10:30 PM
$MSCLF Nice week..Great stuff ahead..
0 · Reply
obryanjfg
obryanjfg Jan. 15 at 11:01 AM
$MSCLF The 1a is 5 boys and all quite advanced stage. I'm not really expecting any dramatic data on efficacy from the 1a, esp at 3 months (March/April) after the restart. The phase 2 maybe, but 1st data from it should be June/July at earliest; however its PBO RCT so what data will they have?
2 · Reply
Florestan
Florestan Jan. 15 at 6:39 AM
$MSCLF 😂🤝
0 · Reply
bradbluett
bradbluett Jan. 14 at 6:29 PM
$MSCLF any ideas as to where or why the interest is coming from^. Been patient with this for over a year. Is there more upside in the near future or is this a short lived rally to draw people in and then dump it
1 · Reply
Florestan
Florestan Jan. 9 at 4:06 AM
$MSCLF this is happening on the back of very little dollar volume. Everyone is early at these prices. I do think we will see a good signal in the coming adult readout and launch us into dollar territory. I am hopeful we will see strong efficacy at the pediatric interim in Q2, potentially minimizing if not eliminating the need for a reverse split.
0 · Reply
HamBoneXoXo
HamBoneXoXo Jan. 8 at 9:46 PM
$MSCLF Cool Went from .49 to .61 in a few days. That is just over 20%. Like to see $1 or more before data
0 · Reply
Sunnym15
Sunnym15 Jan. 8 at 5:46 AM
$DTIL I had faith in this but now $MSCLF is the runner up for DMD
2 · Reply
Latest News on MSCLF
No data available.
Florestan
Florestan Jan. 21 at 3:55 AM
$MSCLF imminent data drop on durability from the adult cohort...First returning patient dosed Oct 21, exactly 3 months ago.
0 · Reply
WBinthehouse
WBinthehouse Jan. 20 at 2:49 PM
$MSCLF up 3 cents on 4K shares. lol. Someone is walking this up to lure suckers.
1 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Jan. 18 at 12:28 AM
$MSCLF just the beginning of a massive re-rate of this stock.
0 · Reply
stevetripp
stevetripp Jan. 16 at 10:30 PM
$MSCLF Nice week..Great stuff ahead..
0 · Reply
obryanjfg
obryanjfg Jan. 15 at 11:01 AM
$MSCLF The 1a is 5 boys and all quite advanced stage. I'm not really expecting any dramatic data on efficacy from the 1a, esp at 3 months (March/April) after the restart. The phase 2 maybe, but 1st data from it should be June/July at earliest; however its PBO RCT so what data will they have?
2 · Reply
Florestan
Florestan Jan. 15 at 6:39 AM
$MSCLF 😂🤝
0 · Reply
bradbluett
bradbluett Jan. 14 at 6:29 PM
$MSCLF any ideas as to where or why the interest is coming from^. Been patient with this for over a year. Is there more upside in the near future or is this a short lived rally to draw people in and then dump it
1 · Reply
Florestan
Florestan Jan. 9 at 4:06 AM
$MSCLF this is happening on the back of very little dollar volume. Everyone is early at these prices. I do think we will see a good signal in the coming adult readout and launch us into dollar territory. I am hopeful we will see strong efficacy at the pediatric interim in Q2, potentially minimizing if not eliminating the need for a reverse split.
0 · Reply
HamBoneXoXo
HamBoneXoXo Jan. 8 at 9:46 PM
$MSCLF Cool Went from .49 to .61 in a few days. That is just over 20%. Like to see $1 or more before data
0 · Reply
Sunnym15
Sunnym15 Jan. 8 at 5:46 AM
$DTIL I had faith in this but now $MSCLF is the runner up for DMD
2 · Reply
Florestan
Florestan Jan. 8 at 3:53 AM
$MSCLF Oppenheimer opened coverage with a PT of 7 CAD (5 USD), 10x from current price. "Nearly all investigational/approved DMD treatments are IV dystrophin, which helps maintain the integrity of muscles and mitigates contraction- dystrophin suggests that genetic modifications could also ameliorate the DMD dystrophin signaling (rather than dystrophin levels) implicated in regeneration of muscles. Early open-label data (N=5) appear promising, while additional open-label randomized PhII data in 2H26 could drive ~300–500%+ upside (see $CAPR +370% move), thus MSCLF is a potentially significant arbitrage opportunity (EV≈$50M vs. > $2B mean EV for nine DMD companies). We initiate coverage of Satellos (MSCLF) with an Outperform rating and a PT of C$7."
2 · Reply
HamBoneXoXo
HamBoneXoXo Jan. 7 at 4:20 PM
$MSCLF Probably dosed the first already.
0 · Reply
WBinthehouse
WBinthehouse Jan. 7 at 3:55 PM
$MSCLF up 7% on 20K shares. Huge lot of bids and ask (Avg 50K) from their 185 million outstanding shares. Totally trying to sucker you in.
1 · Reply
nittanykid
nittanykid Jan. 6 at 1:05 AM
$MSCLF Update posted today on the clinical trials page that they are now enrolling for phase 2. https://clinicaltrials.gov/study/NCT07287189?term=Satellos&rank=1&tab=history&a=3&b=4#version-content-panel
0 · Reply
WBinthehouse
WBinthehouse Jan. 5 at 6:30 PM
$MSCLF BoneHead gobbling this up on 8k shares. lol
0 · Reply
PennyScam
PennyScam Jan. 5 at 3:03 PM
$MSCLF Great work Steve. You got in at the right time. I would remain focused on what they are not talking about. What do they not want you to focus on? Crazy K
0 · Reply
PennyScam
PennyScam Jan. 5 at 2:56 PM
$MSCLF Sounds good. I’m here for ICO Therapeutic‘s ophthalmology indication. Don’t care about this other shit. Frank Fleeson used to work for Astra Zeneca. He‘s a finance guy. Brian Bloom got in like a wet t-shirt. Great job. Super easy call. He liked the potential of this deal so much that he double dipped. I think Brian knows something we don’t. I believe we‘re waiting for rollover. That’s just me. Why would someone over leverage and double dip on some unproven drug. I’ve invested millions in drugs. Never that early for me unless I know theres a possible sweetener or hidden treasure Involved. I need something to motivate me. I’m thinking he likes the idea of Astra Zeneca coming in to buy the remaining indications for the Bertiliumumab drug which Alexion Inc. purchased from my company Immune Pharmaceuticals back in 2021. ICO Therapeutics was the master of Bert back in 2014. That was a fun time. Crazy K
0 · Reply
Florestan
Florestan Dec. 30 at 3:53 PM
$MSCLF Perhaps this is what got our little WBinthehouse so scared...The fact that rescuing skeletal-muscles would potentially prompt the muscles to naturally release exosomes needed to help the heart, without the need of Deramiocel's CDC exosomes. I do think the therapies are complementary, and only fools would think 1 drug alone could fix DMD.
0 · Reply
WBinthehouse
WBinthehouse Dec. 30 at 3:21 PM
$MSCLF 500 shares traded really? Did you buy this lol
1 · Reply
HamBoneXoXo
HamBoneXoXo Dec. 29 at 5:18 PM
$MSCLF Accumulating at these prices
0 · Reply
Florestan
Florestan Dec. 29 at 4:20 AM
$MSCLF convergence of biological effect across the species. This is a 1B company when P2 reports RCT interim in Q2.
0 · Reply
Florestan
Florestan Dec. 29 at 3:36 AM
$MSCLF I find this opinion to be comical because by this logic, every drug developer should be trading at 0, all the time. Do you even understand what cash value mean? Or time value of money/discounted cashflow? Do you understand how biotechs work at all?
2 · Reply